COMPANY

GT Biopharma

HQ: San Francisco, CA source · gtbiopharma.com ↗ · West Coast

Keywords: oncology High-risk Myelodysplastic Syndromes Acute Myelogenous Leukemia Systemic Mastocytosis Mast Cell Leukemia

Location: San Francisco, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

SEC Form D raise Raised $7.75M (Form D filed Sep 29, 2026). SEC Form D 0000109657-26-000001 (Sep 29, 2026)
Evidence (1 event)
- Sep 29, 2026 · SEC Form D 0000109657-26-000001
  Name of Issuer: GT Biopharma, Inc.; CIK: 109657; Address: San Francisco, CA; Submission type: D; Filing date: 2026-09-29; Industry Group: Biotechnology; Date of First Sale: 2026-09-14; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 38958054; Total Amount Sold: 7750000; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Jan 1, 2020 Trial start Phase 1/Phase 2: GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT03214666	GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies	Phase 1/Phase 2	Terminated	Jan 1, 2020	Aug 2, 2021 (actual)

Form D raises come from the company’s own SEC filing (last 2 years).

2026-09-29 Raise Private raise (SEC Form D): $7.8M sold of $39.0M offered; issuer “GT Biopharma, Inc.”. Verified from the SEC filing. SEC filing ↗
2025-05-28 Raise Private raise (SEC Form D): amount sold not stated; issuer “GT Biopharma, Inc.”. Verified from the SEC filing. SEC filing ↗
2025-05-27 Raise Private raise (SEC Form D): $6.0M sold; issuer “GT Biopharma, Inc.”. Verified from the SEC filing. SEC filing ↗
2025-03-07 Raise Private raise (SEC Form D): $1.3M sold; issuer “GT Biopharma, Inc.”. Verified from the SEC filing. SEC filing ↗